eFlow® Rapid neubliser for the treatment of patients with cystic fibrosis

Falagas, M. E., Michalopoulos, A. & Metaxas, E. I. (2010). 'Pulmonary drug deliverysystems for antimicrobial agents: facts and myths', International Journal ofAntimicrobial Agents, 35 (2), 101-106.Heijerman, H., Westerman, E. et al (2009). 'Inhaled medication and inhalation devicesfor lung disease in patients with cystic fibrosis: A European consensus', Journal ofCystic Fibrosis, 8 (5), 295-315.Hubert, D., Leroy, S. et al (2009). 'Pharmacokinetics and safety of tobramycinadministered by the PARI eFlow rapid nebulizer in cystic fibrosis', J Cyst Fibros, 8(5), 332-337.Hureaux, J., Lagarce, F. et al (2009). 'Lipid nanocapsules: ready-to-use nanovectorsfor the aerosol delivery of paclitaxel', Eur J Pharm Biopharm, 73 (2), 239-246.Lass, J. S., Sant, A. & Knoch, M. (2006). 'New advances in aerosolised drug delivery:Vibrating membrane nebuliser technology', Expert Opinion on Drug Delivery, 3 (5),693-702.PARI GmbH (2008). Aerosol: Delivery with eFlow ® Technology [Internet]. Availablefrom: http://www.paripharma.com/technologies1.htm [Accessed 29th September].Rottier, B. L., van Erp, C. J. et al (2009). 'Changes in performance of the Pari eFlowrapid and Pari LC Plus during 6 months use by CF patients', J Aerosol Med PulmDrug Deliv, 22 (3), 263-269.Traini, D. & Young, P. M. (2009). 'Delivery of antibiotics to the respiratory tract: Anupdate', Expert Opinion on Drug Delivery, 6 (9), 897-905.SEARCH CRITERIA TO BE USED:Administration, InhalationAnti-Bacterial Agents/administration & dosage/*pharmacokineticsCross-Over StudiesCystic Fibrosis/*complicationsLung DiseasesNebulizers and VaporizersAerosolsCystic Fibrosis/*drug therapyHEALTH PACT DECISION: Horizon Scanning Report Full Health Technology Assessment Monitor Archive Refer Decision pendingPRIORITY RATING High Medium Low12 eFlow Rapid nebuliser: November 2010